{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:27:40Z","timestamp":1787016460085,"version":"build-2736575974"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Contrat Innovation, Region Occitanie","award":["grant 20006316"],"award-info":[{"award-number":["grant 20006316"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,3,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      ANT3310 is a novel broad-spectrum diazabicyclooctane serine \u03b2-lactamase inhibitor being developed in combination with meropenem (MEM) for the treatment of serious infections in hospitalized patients where carbapenem-resistant Gram-negative pathogens are expected. In this study, we evaluated the\n                      <jats:italic>in vitro<\/jats:italic>\n                      antibacterial activity of MEM in the presence of ANT3310 at 8 \u00b5g\/mL against global clinical isolates that included\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      = 905), carbapenem-resistant Enterobacterales (CRE), carrying either oxacillinase (OXA) (\n                      <jats:italic>n<\/jats:italic>\n                      = 252) or\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      carbapenemase (KPC) (\n                      <jats:italic>n<\/jats:italic>\n                      = 180) carbapenemases, and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (\n                      <jats:italic>n<\/jats:italic>\n                      = 502). MEM was poorly active against\n                      <jats:italic>A. baumannii,<\/jats:italic>\n                      as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and imipenem-relebactam (MIC\n                      <jats:sub>90<\/jats:sub>\n                      values of \u226532 \u00b5g\/mL). On the other hand, MEM-ANT3310 displayed an MIC\n                      <jats:sub>90<\/jats:sub>\n                      value of 4 \u00b5g\/mL, similar to that observed with sulbactam-durlobactam, a drug developed to specifically treat\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      infections. ANT3310 (8 \u00b5g\/mL) additionally restored the activity of MEM against OXA- and KPC-producing CREs decreasing MEM MIC\n                      <jats:sub>90<\/jats:sub>\n                      values from &gt;32 \u00b5g\/mL to 0.25 and 0.5 \u00b5g\/mL, respectively. The combination of 8 \u00b5g\/mL of both MEM and ANT3310 prevented growth of 97.5% of\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      and 100% of OXA- and KPC-positive CREs, with ~90% of\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      isolates also displaying MEM MICs \u22648 \u00b5g\/mL. Furthermore, MEM-ANT3310 was efficacious in both thigh and lung murine infection models with OXA-23\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      . This study demonstrates the potent\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity of the MEM-ANT3310 combination against both carbapenem-resistant\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      and Enterobacterales clinical isolates, a key differentiator to other \u03b2-lactam\/\u03b2-lactamase combinations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01120-23","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T09:00:24Z","timestamp":1706605224000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Meropenem-ANT3310, a unique \u03b2-lactam-\u03b2-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant\n                    <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-0188","authenticated-orcid":false,"given":"Magdalena","family":"Zalacain","sequence":"first","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Achard","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Llanos","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[{"name":"IHMA Europe, Monthey\/VS, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[{"name":"IHMA Europe, Monthey\/VS, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Holden","sequence":"additional","affiliation":[{"name":"Evotec, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Toomey","sequence":"additional","affiliation":[{"name":"Evotec, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Davies","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Leiris","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Sable","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Ledoux","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Bousquet","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Castandet","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Lozano","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Everett","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lemonnier","sequence":"additional","affiliation":[{"name":"Antabio SAS, Lab\u00e8ge, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_3_4_2","unstructured":"O\u2019Neill J. 2016. Review on antimicrobial resistance - tackling drug-resistant infections globally: final report and recommendations. Available from: https:\/\/amr-review.org\/home.html"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_3_8_2","unstructured":"ECDC. 2020. Antimicrobial resistance in the EU\/EEA (EARS-net). Annual epidemiological report for 2019. European Centre for Disease Prevention and Control (Stockholm). Available from: https:\/\/www.ecdc.europa.eu\/...\/surveillance-antimicrobial-resistance-Europe-2019.pdf"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jam.15130"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.03.014"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2019-0098"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01535"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1756775"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257225"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.06.012"},{"key":"e_1_3_3_18_2","volume-title":"Document M100-S33","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. Performance standards for antimicrobial susceptibility testing. In Document M100-S33, 33rd ed. CLSI, Wayne, PA.","edition":"33"},{"key":"e_1_3_3_19_2","unstructured":"EUCAST. 2023. Breakpoint tables for interpretation of MICs and zone diameters. Version 13 valid from 2023-01-01. Available from: https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01446-17"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24030653"},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","unstructured":"Tamma PD Aitken SL Bonomo RA Mathers AJ van Duin D Clancy CJ. 2023. Infectious diseases society of America antimicrobial-resistant treatment guidance: gram-negative bacterial infections. Infectious Diseases Society of America. Available from: https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_3_24_2","unstructured":"FDA. 2023. Rationale for polymyxin breakpoints for enterobacterales Pseudomonas aeruginosa and Acinetobacter spp. Available from: https:\/\/www.fda.gov"},{"key":"e_1_3_3_25_2","unstructured":"FDA. 2023. Susceptibility test interpretive criteria recognized or otherwise identified by FDA. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01120-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01120-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T09:02:53Z","timestamp":1709715773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01120-23"}},"subtitle":[],"editor":[{"given":"Boudewijn L.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,6]]}},"alternative-id":["10.1128\/aac.01120-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01120-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"2023-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01120-23"}}